Overall, our findings provide moderate evidence that carriers of CYP2C19 LOF alleles derive less benefit from clopidogrel treatment after ischemic stroke or TIA, suggesting that CYP2C19 genetic testing may be considered to personalize antiplatelet therapy in non-East Asian patients. The gene discussed is CYP2C19; the disease is ischemic stroke.